


SACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: COMPARISON OF OUR DATA TO THE ASCENT TRIAL AFTER 2 YEARS OF EXPERIENCE

L. DHO, A. MAIRE, C. LEVENBRUCK, J. COUSSIROU, D. ZERBIB, F. DE CROZALS

Institut Sainte-Catherine (ISC), 250 chemin de Baigne Pieds, 84 918 Avignon, France

lucile.dho@etu.univ-amu.fr



▶▶ BACKGROUND AND IMPORTANCE

Sacituzumab govitecan (SG) is an **antibody-drug conjugate** used in metastatic triple-negative breast cancer (TNBCm) since 2021.

▶▶ AIM AND OBJECTIVE

Adverse events were monitored during the Ascent Trial (AT).

⇒ Physical desk reference.

▶ Over selected population?

Early access

September 2021 in France for TNBCm.

Are adverse events in our hospital similar to the ascent trial ?

▶ Comparison of our data to the AT.

▶▶ MATERIALS AND METHODS

- Retrospective monocentric study.
- Subjects: patients with metastatic TNBC treated by SG from May 2021 to July 2023.
- Comparison of our data to the Ascent's Trial (AT) (*Bardia et al., NEJM, 2021*).
- We monitored their general state, the number of treatments and metastatic sites they had before the first cycle, the types and grades of AE and how we managed them.

▶▶ RESULTS

GROUPS		*ISC	AT
Number of patients		25	235
Medium age		62	54
Median number of lines before SG		4	4
ECOG	0	56%	43%
	1	32%	57%
	2	12%	0%

AE	*ISC	AT
Neutropenia	56%	63%
G3 neutropenia	24%	51%
Growth factors	68%	49%
Asthenia	52%	45%
Nausea	44%	57%
Diarrhea	52%	59%
G3 diarrhea	20%	10%

* ISC = Institut Sainte-Catherine, Avignon.

Dose reductions were more frequent in our group compared to the AT (60% versus 22%).

28% of our patients had **to skip** at least one **cycle**.

3 patients had to **change line** because of AE.

▶▶ CONCLUSION AND RELEVANCE

Pharmaceutical expertise and talks with oncologists play an important role in patients' care.

Atropine is used as premedication since June 2023 **to prevent diarrhea**.

Comparison of **dose-intensity and median progression-free survival** of our patients to the AT is to be done in the next months.

